Is Marksans Pharma a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Marksans Pharma Ltd is a average quality company .

Is Marksans Pharma undervalued or overvalued?

The key valuation ratios of Marksans Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Marksans Pharma share price return in the past 10 years?

Marksans Pharma Ltd share price has appreciated 17.2% annually (CAGR) over the past ten years.

Is Marksans Pharma a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Marksans Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Marksans Pharma Ltd - Stock Valuation and Financial Performance

Name: Marksans Pharma
Brand: Marksans Pharma

BSE: 524404 | NSE: MARKSANS | Pharmaceuticals & Drugs | Small Cap

Place order

Marksans Pharma Share Price

₹309 3.15 1.03%
as on 21-Nov'24 16:00

10 Year X-Ray of Marksans Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	33.4%	22.5%	3.4%	4.9%	12%	11.4%	23.5%	19.9%	14.3%	14.8%	-
Value Creation Index ⓘ	1.4	0.6	-0.8	-0.7	-0.1	-0.2	0.7	0.4	0.0	0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	406	358	216	295	424	433	600	658	655	853	1,030
Sales YoY Gr.	-	-11.7%	-39.7%	36.5%	44%	2.2%	38.3%	9.8%	-0.5%	30.2%	-
Adj EPS ⓘ	1.5	1.7	0.1	0.2	1	0.9	2.4	2.2	1.8	2.8	3.4
YoY Gr.	-	13.6%	-94%	80%	450%	-6.1%	160.2%	-9.5%	-16.4%	54.1%	-
BVPS (₹) ⓘ	8.5	10	10.2	10.5	11.5	12.4	14.7	16.9	24.5	27	28.5
Adj Net Profit ⓘ	60.3	68.3	3.9	7.3	40.7	37.9	99.1	89.5	83.1	128	154
Cash Flow from Ops. ⓘ	112	64.8	-13.6	15.6	19.8	108	107	56	51.7	34.1	-
Debt/CF from Ops. ⓘ	0.5	0.6	-5.4	4.3	3.9	0	0	0.1	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.6%	15%	12.5%	30.2%
Adj EPS ⓘ	7.5%	23.3%	5.2%	54.1%
BVPSⓘ	13.8%	18.6%	22.6%	10%
Share Price	17.2%	83.1%	75.6%	122.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	23.3	17.5	0.9	1.7	9	7.8	17.9	12.9	8.8	11	12.2
Op. Profit Mgn % ⓘ	26.1	27.8	6.3	9.9	14.9	16.5	19.1	17.3	12.8	16.4	16.5
Net Profit Mgn % ⓘ	14.9	19.1	1.8	2.5	9.6	8.8	16.5	13.6	12.7	15	14.9
Debt to Equity ⓘ	0.1	0.1	0.2	0.2	0.2	0	0	0	0	0	0
Working Cap Days ⓘ	185	206	352	278	223	227	165	187	238	253	170
Cash Conv. Cycle ⓘ	102	127	260	208	160	157	105	121	146	143	119

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 12.20%

Sales growth is growing at healthy rate in last 3 years 12.48%

Sales growth is good in last 4 quarters at 44.37%

Net Profit has been subdued in last 3 years 5.23%

Latest Financials - Marksans Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	3.4	7.7
TTM Sales (₹ Cr.)	1,030	2,379
BVPS (₹.) ⓘ	28.5	50.3
Reserves (₹ Cr.) ⓘ	1,246	2,236
P/BV ⓘ	10.74	6.08
PE ⓘ	90.29	39.94

From the Market
52 Week Low / High (₹)	126.05 / 328.35
All Time Low / High (₹)	0.70 / 328.35
Market Cap (₹ Cr.)	13,860
Equity (₹ Cr.)	45.3
Face Value (₹)	1
Industry PE ⓘ	43

Management X-Ray of Marksans Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Marksans Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Marksans Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	406	358	216	295	424	433	600	658	655	853
Operating Expenses ⓘ	300	259	202	266	361	362	486	545	582	713
Manufacturing Costs	23	22	19	19	21	18	23	17	40	76
Material Costs	218	178	112	169	236	245	338	378	394	479
Employee Cost	24	26	40	46	46	49	55	60	56	77
Other Costs ⓘ	35	33	31	32	57	50	70	90	91	81
Operating Profit ⓘ	106	99	14	29	63	71	114	114	73	140
Operating Profit Margin (%)	26.1%	27.7%	6.3%	9.9%	14.9%	16.5%	19.0%	17.3%	11.1%	16.4%
Other Income ⓘ	13	13	18	7	8	0	31	42	79	62
Interest ⓘ	13	6	4	8	7	7	5	4	4	1
Depreciation ⓘ	9	15	15	12	9	12	15	18	17	29
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	97	92	12	17	56	53	124	135	132	172
Tax ⓘ	30	20	0	4	12	15	26	31	29	38
Profit After Tax	67	71	12	12	44	38	98	104	103	134
PAT Margin (%)	16.5%	20.0%	5.3%	4.2%	10.3%	8.7%	16.4%	15.8%	15.7%	15.7%
Adjusted EPS (₹)	1.6	1.8	0.3	0.3	1.1	0.9	2.4	2.5	2.3	3.0
Dividend Payout Ratio (%)	7%	7%	18%	16%	5%	11%	10%	10%	22%	20%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	358	423	419	429	471	506	600	692	1,111	1,223
Share Capital ⓘ	53	53	41	41	41	41	41	41	45	45
Reserves ⓘ	305	369	378	388	430	465	559	651	1,066	1,177
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	44	41	73	66	77	0	0	5	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	44	41	73	66	77	0	0	5	0	0
Trade Payables	45	31	21	34	37	57	64	74	112	160
Others Liabilities ⓘ	81	39	33	31	40	48	97	218	146	166
Total Liabilities ⓘ	527	534	546	560	625	610	761	989	1,369	1,548
Fixed Assets
Gross Block	162	184	196	202	225	249	277	301	319	473
Accumulated Depreciation	72	87	102	114	122	134	148	166	175	201
Net Fixed Assetsⓘ	90	97	94	88	103	115	129	136	144	272
CWIP ⓘ	0	0	0	0	0	0	0	0	4	0
Investmentsⓘ	68	231	234	236	236	236	236	237	266	293
Inventories	51	44	29	42	70	75	94	104	131	191
Trade Receivables	125	133	155	169	178	162	169	247	305	370
Cash Equivalents	168	3	3	1	2	3	106	224	440	312
Others Assetsⓘ	26	25	31	24	36	19	27	43	78	111
Total Assets ⓘ	527	534	546	560	625	610	761	989	1,369	1,548

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	112	65	-14	16	20	108	107	56	52	34
PBT ⓘ	97	92	12	17	56	53	124	135	132	172
Adjustment ⓘ	18	9	13	20	12	19	-9	-8	11	-16
Changes in Working Capital ⓘ	29	-15	-22	-16	-35	46	12	-39	-60	-83
Tax Paid ⓘ	-31	-20	-16	-5	-13	-10	-20	-32	-32	-39
Cash Flow From Investing Activity ⓘ	-29	-177	-8	-8	-20	-24	9	-128	-195	-114
Capex	-32	-22	-12	-6	-23	-24	-21	-23	-35	-155
Net Investments	0	-164	-3	-2	0	0	0	-120	-149	-4
Others ⓘ	3	9	7	0	3	0	29	15	-10	45
Cash Flow From Financing Activityⓘ	51	-52	21	-10	1	-82	-14	71	210	-26
Net Proceeds from Shares ⓘ	131	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-6	-3	-4	-8	-7	-7	-5	-3	-4	0
Dividend Paid ⓘ	-6	-7	-6	-2	-2	-2	-4	-11	-10	-23
Others ⓘ	-68	-42	31	0	10	-72	-4	85	224	-4
Net Cash Flow ⓘ	134	-164	-1	-2	1	2	102	-1	67	-106

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	27.27	18.91	2.79	2.93	9.7	7.77	17.8	16.11	11.41	11.46
ROCE (%)	33.41	22.45	3.44	4.92	11.99	11.39	23.46	19.91	14.27	14.81
Asset Turnover Ratio	0.9	0.67	0.4	0.53	0.72	0.7	0.88	0.76	0.59	0.59
PAT to CFO Conversion(x)	1.67	0.92	-1.17	1.33	0.45	2.84	1.09	0.54	0.5	0.25
Working Capital Days
Receivable Days	107	132	244	200	149	143	100	114	145	144
Inventory Days	48	48	62	44	48	61	51	54	62	69
Payable Days	71	78	84	59	55	70	65	67	86	103

Marksans Pharma Ltd Stock News

Marksans Pharma Ltd FAQs

What is the share price of Marksans Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Marksans Pharma on 21-Nov-2024 16:00 is ₹309.0.

What is the market cap of Marksans Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:00 the market cap of Marksans Pharma stood at ₹13,860.

What is the P/E ratio of Marksans Pharma?

The latest P/E ratio of Marksans Pharma as of 21-Nov-2024 16:00 is 90.29.

What is the P/B ratio of Marksans Pharma?

The latest P/B ratio of Marksans Pharma as of 21-Nov-2024 16:00 is 10.74.

What is the 52-week high and low of Marksans Pharma?

The 52-week high of Marksans Pharma is ₹328.4 and the 52-week low is ₹126.0.

What is the TTM revenue of Marksans Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Marksans Pharma is ₹1,030 ( Cr.) .

About Marksans Pharma Ltd

Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.

Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.

The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.

Marksans Pharma acquired Relonchem, a leading UK-based generic pharmaceutical company. This acquisition gave company an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe.

Marksans Pharma exports its products to markets in Europe, Latin America, Africa and Oceania.

In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited

Business area

Research and Development- The companyâ€™s R&D centre is situated in Goa and is engaged in new drug discovery chemistry, pharmacokinetics, pharmacology/ molecular biology, toxicology, and related skills and support areas.

Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in Asia. The companyâ€™s manufacturing plants are located at Goa and UK.

APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.

CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.

Milestones

2009 - Marksans Pharma establlished itself as a global player
2008 - Acquired Bells, Sons & Co. (Druggists) Ltd.
Acquired Relonchem Limited
2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.
2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd.
Changed its name to "Marksans Pharma Ltd"
2001 - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.